Scinai Immunotherapeutics Ltd (SCNI)
Company Info
Highlights
$2.69M
$658.00K
-$580.00K
$9.45M
$1.90 - $6.97
$700.00
0.04%
0.03
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Scinai Immunotherapeutics Ltd (SCNI) returned -19.58% year-to-date (YTD) and -30.67% over the past 12 months. Over the past 10 years, SCNI returned -39.87% annually, underperforming the S&P 500 benchmark at 10.85%.
SCNI
-19.58%
5.49%
-22.25%
-30.67%
-72.55%
-73.32%
-39.87%
^GSPC (Benchmark)
0.51%
6.15%
-2.00%
12.92%
12.68%
14.19%
10.85%
Monthly Returns
The table below presents the monthly returns of SCNI, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 7.29% | -1.36% | -23.90% | -2.06% | 1.96% | -19.58% | |||||||
| 2024 | -20.98% | 4.34% | 5.72% | -12.31% | -17.60% | -25.86% | 67.63% | -19.96% | -7.51% | 3.19% | -3.37% | -2.76% | -43.82% |
| 2023 | -11.82% | -9.77% | -8.28% | -10.65% | -8.29% | -20.34% | -5.67% | 1.50% | -35.56% | -24.14% | 8.94% | -17.19% | -79.89% |
| 2022 | -44.26% | -3.05% | 30.71% | -22.29% | 3.88% | -13.06% | 2.58% | -7.53% | -33.94% | 3.99% | 28.57% | -69.67% | -87.40% |
| 2021 | 61.92% | -12.53% | -4.52% | -15.79% | -5.31% | -5.28% | 1.74% | -7.88% | -18.22% | -5.45% | -17.31% | 36.63% | -16.37% |
| 2020 | 17.76% | -25.23% | -5.87% | 75.32% | 47.41% | 14.32% | 50.46% | 9.52% | 4.27% | -92.33% | 8.67% | -13.80% | -69.75% |
| 2019 | 10.69% | -8.52% | 12.42% | 32.41% | -7.65% | -13.25% | 16.49% | -12.07% | 0.95% | -8.50% | 6.02% | 60.79% | 94.76% |
| 2018 | 35.45% | -17.36% | -9.45% | 11.36% | 5.95% | 4.06% | -11.55% | -3.14% | -2.00% | -4.47% | 10.28% | -19.15% | -11.01% |
| 2017 | 50.75% | 18.81% | -3.33% | 12.93% | 12.98% | 18.71% | 8.37% | -16.28% | -10.29% | 2.10% | -20.28% | -7.89% | 60.00% |
| 2016 | -9.09% | 12.50% | -7.90% | 6.17% | -9.09% | -2.78% | -5.43% | 17.22% | -5.15% | 5.98% | -5.64% | -8.97% | -15.40% |
| 2015 | 9.02% | 13.79% | -14.14% | -17.64% | 4.85% | 5.99% | -1.24% | 3.08% | -0.75% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of SCNI is 38, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Scinai Immunotherapeutics Ltd (SCNI) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Scinai Immunotherapeutics Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Scinai Immunotherapeutics Ltd was 99.96%, occurring on Apr 15, 2025. The portfolio has not yet recovered.
The current Scinai Immunotherapeutics Ltd drawdown is 99.95%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.96% | Jul 14, 2020 | 1196 | Apr 15, 2025 | — | — | — |
| -61.86% | Jul 25, 2017 | 357 | Dec 24, 2018 | 259 | Jan 13, 2020 | 616 |
| -53.99% | Jan 30, 2020 | 32 | Mar 16, 2020 | 31 | Apr 29, 2020 | 63 |
| -39.76% | Jun 29, 2015 | 294 | Nov 23, 2016 | 45 | Feb 9, 2017 | 339 |
| -26.79% | May 22, 2020 | 14 | Jun 11, 2020 | 8 | Jun 23, 2020 | 22 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Scinai Immunotherapeutics Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Scinai Immunotherapeutics Ltd, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 24.2% positive surprise.
Valuation
The Valuation section provides an overview of how Scinai Immunotherapeutics Ltd is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for SCNI, comparing it with other companies in the Biotechnology industry. Currently, SCNI has a P/E ratio of 0.0. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for SCNI relative to other companies in the Biotechnology industry. Currently, SCNI has a P/S ratio of 4.1. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for SCNI in comparison with other companies in the Biotechnology industry. Currently, SCNI has a P/B value of 0.6. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |